DB16286InvestigationalVaccines
Pemlimogene merolisbac is under investigation in clinical trial NCT03371381 (An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in...
- Also known as
- Ladd listeria monocytogenes jnj-64041757 · Live-attenuated listeria monocytogenes encoding egfrviii-mesothelin vaccine jnj-64041757 · Recombinant live-attenuated double-deleted (ladd) strain of listeria monocytogenes (lm .delta.acta/.delta.inlb) expressing a fusion protein comprising the n-terminal 100 amino acids of the lm acta protein (actan100), 5 tandem copies of a 21 amino acid fr
- Code names
- ADU-214 · JNJ-64041757
Resolves to
Compound
What you can answer from here — as of April 23, 2025
Which companies are running trials of Pemlimogene merolisbac, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account